Destiny Pharma, as an NBIC industrial partner, is currently working on three NBIC funded research projects in collaboration with expert teams at the Universities of Cardiff, Sheffield and Southampton.
The XF drug platform has demonstrated efficacy against bacteria in biofilms and we are looking forward to advancing these research assets towards clinical trials. Bacterial and fungal biofilms play an important role in a range of serious conditions, ranging from catheter-associated infections, chronic wound infections, ventilator-associated pneumonia and chronic infections in cystic fibrosis.
For further information, click on link below:
NBIC Launch #BiofilmAware Campaign